Infant Bacterial Therapeutics AB (publ) (IBT-B.ST)
- Previous Close
87.20 - Open
86.00 - Bid 85.00 x --
- Ask 86.00 x --
- Day's Range
85.00 - 86.80 - 52 Week Range
41.30 - 106.50 - Volume
1,551 - Avg. Volume
6,601 - Market Cap (intraday)
1.175B - Beta (5Y Monthly) 1.01
- PE Ratio (TTM)
-- - EPS (TTM)
-9.95 - Earnings Date May 7, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe disease in infants. The company was incorporated in 2011 and is based in Stockholm, Sweden.
www.ibtherapeutics.comRecent News: IBT-B.ST
Performance Overview: IBT-B.ST
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IBT-B.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IBT-B.ST
Valuation Measures
Market Cap
1.17B
Enterprise Value
845.64M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.85
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-6.92
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-24.01%
Return on Equity (ttm)
-38.65%
Revenue (ttm)
77k
Net Income Avi to Common (ttm)
-123.07M
Diluted EPS (ttm)
-9.95
Balance Sheet and Cash Flow
Total Cash (mrq)
329.06M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-64.36M
Company Insights: IBT-B.ST
IBT-B.ST does not have Company Insights